A xanthocyanin-encapsulated composition, its preparation method and application

Abstract

This invention discloses a xanthocyanin-encapsulated composition, its preparation method, and its application, belonging to the field of cosmetic active delivery technology. Addressing the problems of poor solubility and low transdermal absorption efficiency of xanthocyanin, this invention provides two encapsulation systems: one uses methyl-β-cyclodextrin as the encapsulation material, preparing a cyclodextrin inclusion complex by incubation at 60℃ for 4 hours, significantly improving the water solubility of xanthocyanin; the other uses lecithin and cholesterol as membrane materials, adding Tween 80 and combining with ultrasonic treatment to prepare a lipid carrier, improving the system's stability. In vitro transdermal experiments show that after 8 hours, the cumulative permeation rate of the cyclodextrin inclusion complex reaches 8.92%, and the lipid carrier reaches 5.64%, far exceeding the 2.85% of free xanthocyanin. This invention has a simple and feasible process, effectively improving the application limitations of xanthocyanin, and can be used in the development of skincare cosmetics.

Description

Technical Field

[0001] This invention belongs to the field of cosmetic active ingredient delivery technology, specifically relating to a zanthoxylin-encapsulated composition and its preparation method and application. Background Technology

[0002] Zanthoxylum bungeanum (also known as WGX-50) is an aromatic amide compound extracted and isolated from the dried, ripe fruit of Zanthoxylum bungeanum Maxim., Sichuan pepper, China. Its chemical structure is N-(3,4-dimethoxyphenylethyl)-3-phenylacrylamide, and it can be obtained through total chemical synthesis. Current research indicates that zanthoxylum bungeanum possesses various skincare benefits, including anti-aging, moisturizing, whitening, and anti-inflammatory effects. At the histological level, it can rejuvenate aging skin and promote collagen expression; at the cellular level, it can inhibit β-galactosidase activity, delaying cell aging; simultaneously, it can regulate the expression of moisturizing and whitening-related genes and alleviate skin inflammation, making it a highly promising active ingredient for cosmetics.

[0003] However, xanthocyanin has inherent defects such as poor water solubility and low solubility, making it difficult to stably add and disperse in water-based cosmetic formulations. At the same time, the barrier function of the stratum corneum of the skin restricts the penetration of active ingredients, making it difficult for xanthocyanin to reach the site of action and exert its effects, which seriously restricts its practical application in cosmetics.

[0004] Cyclodextrin inclusion and liposome encapsulation are commonly used active ingredient delivery technologies in the cosmetics industry. The former can enhance water solubility by encapsulating poorly soluble substances through hydrophobic cavities, while the latter can improve skin affinity and transdermal efficiency through biomembrane-like structures. However, systematic research on the optimization of xanthocyanin encapsulation processes, stability control, and transdermal effects is still relatively lacking, which cannot provide sufficient technical support for its industrial application. Summary of the Invention

[0005] To address the problems of poor solubility, poor formulation stability, and low transdermal absorption efficiency of xanthocyanin in existing technologies, this application designs a xanthocyanin-encapsulated composition and its preparation method. Through optimization of process parameters and formulation, xanthocyanin cyclodextrin inclusion complex and xanthocyanin lipid carrier are prepared respectively, effectively improving the water solubility, formulation stability, and transdermal performance of xanthocyanin, providing a technical basis for its application in cosmetics.

[0006] A method for preparing a xanthocyanin-encapsulated composition, wherein the encapsulated composition is a xanthocyanin cyclodextrin inclusion complex or a xanthocyanin lipid carrier; When the encapsulating composition is a xanthocyanin cyclodextrin inclusion complex, the preparation steps include: Step S101: Add methyl-β-cyclodextrin to deionized water, stir and heat until completely dissolved to obtain an aqueous phase; Step S102: Dissolve the xanthocyanin in anhydrous ethanol to obtain the alcohol phase; Step S103: Slowly add the alcohol phase dropwise into the aqueous phase, keep warm and stir to encapsulate; Step S104: After cooling, let stand for 24 hours, filter, wash the filter cake and dry it to constant weight; For every 908 parts by weight of methyl-β-cyclodextrin, there are 249 parts by weight of xanthoside and 20 parts by volume of deionized water. When the encapsulating composition is a xanthocyanin lipid carrier, the preparation steps include: Step S201: Prepare phase A: by mass fraction, lecithin 3%, cholesterol 0.3%, 1,2-propanediol 15%, and xanthocyanin 0.1%, mix and heat and stir until evenly dispersed; Step S202: Prepare phase B: By mass fraction, add Tween 80 2%, deionized water to make up to 100%, and heat. Step S203: Slowly add phase B to phase A, stir and then sonicate, stir and cool to room temperature.

[0007] Preferably, the optimal solution is prepared as follows: Step S101: Add methyl-β-cyclodextrin to deionized water, stir and heat to 60°C until completely dissolved to obtain an aqueous phase; Step S102: Dissolve the xanthocyanin in anhydrous ethanol to obtain the alcohol phase; Step S103: Slowly add the alcohol phase dropwise to the aqueous phase at 60°C, and keep warm and stir for 4 hours to incorporate the alcohol phase. Step S104: After cooling, let stand at 4℃ for 24 hours, filter, wash the filter cake and dry it to constant weight; For every 908 parts by weight of methyl-β-cyclodextrin, there are 249 parts by weight of xanthoside and 20 parts by volume of deionized water. When the encapsulating composition is a xanthocyanin lipid carrier, the preparation steps include: Step S201: Prepare phase A: by mass fraction, lecithin 3%, cholesterol 0.3%, 1,2-propanediol 15%, and xanthocyanin 0.1%, mix and heat to 60℃ and stir until evenly dispersed; Step S202: Prepare phase B: By mass fraction, add Tween 80 2%, deionized water to make up to 100%, and heat to 60°C; Step S203: Slowly add phase B to phase A, stir and then sonicate, stir and cool to room temperature.

[0008] Preferably, in step S104 of the preparation of the xanthocyanin cyclodextrin inclusion complex, the filter cake is washed with anhydrous ethanol and dried by electric heating constant temperature forced air drying.

[0009] Preferably, in step S203 of the preparation of the xanthocyanin lipid carrier, the stirring speed is 600 rpm and the stirring time is 10 min; the ultrasonic treatment is performed using an ultrasonic cell disruptor for 10 min.

[0010] Preferably, in step S203 of preparing the xanthocyanin lipid carrier, stirring and cooling are carried out at room temperature.

[0011] Preferably, in the xanthocyanin lipid carrier, after Tween 80 dissociates, it is coated onto the surface of phospholipid vesicles through electrostatic interaction, increasing the repulsive force between vesicles.

[0012] The above method can be used to prepare a xanthocyanin-encapsulated composition.

[0013] Preferably, a method for enhancing the in vitro transdermal absorption of xanthocyanin involves applying a xanthocyanin-encapsulated composition to isolated skin for transdermal diffusion.

[0014] Preferably, the transdermal experiment was conducted using a Franz vertical diffusion cell, with the full-thickness skin of a pig ear as the transdermal barrier, dimethyl sulfoxide as the receiving solution, and the experimental temperature at 37°C. After 8 hours of transdermal treatment, the cumulative permeability of the xanthocyanin cyclodextrin inclusion complex was not less than 8.5%, and the cumulative permeability of the xanthocyanin lipid carrier was not less than 5.5%.

[0015] In addition, the peppermint-encapsulated composition designed in this application can be used to prepare skin care cosmetics.

[0016] The advantages and effects of this application are as follows: 1. The present application discloses a method for preparing a cyclodextrin-encapsulated composition, which employs a 60°C incubation reaction, dissolving methyl-β-cyclodextrin in 20 parts by volume of deionized water, and an inclusion time of 4 hours for cyclodextrin inclusion. This process ensures that the cyclodextrin is fully dissolved, allowing the cyclodextrin molecules to fully migrate into the hydrophobic cavities of the cyclodextrin, thus achieving full inclusion. The resulting inclusion composition exhibits significantly better solubility in water than free cyclodextrin, and its microstructure changes from lamellar to rod-like, with a stable inclusion state. This effectively solves the problem of poor water solubility of cyclodextrin in formulation applications.

[0017] 2. The method for preparing a xanthocyanin-encapsulated composition designed in this application adopts a lipid carrier preparation process that involves adding 2% Tween 80, combined with ultrasonic cell disruption treatment, and adjusting the xanthocyanin loading to 0.1%. On the one hand, after Tween 80 dissociates, it encapsulates the surface of phospholipid vesicles through electrostatic interaction, increasing the repulsive force between vesicles and effectively slowing down vesicle aggregation and sedimentation. On the other hand, ultrasonic treatment can reduce particle size and improve dispersion uniformity, and reducing the drug loading can reduce the supersaturation precipitation of active ingredients. Ultimately, it significantly improves the room temperature stability and centrifugal stability of the lipid carrier, and the amount of precipitation is significantly reduced.

[0018] 3. The present application discloses a method for preparing a xanthocyanin-encapsulated composition, which prepares xanthocyanin into a cyclodextrin inclusion complex or a lipid carrier for transdermal delivery. This method can effectively assist xanthocyanin in breaking through the skin's stratum corneum barrier and significantly improve the in vitro cumulative permeability. The cumulative permeability of the cyclodextrin inclusion complex can reach 8.92% after 8 hours, and that of the lipid carrier can reach 5.64%, which are 3.1 times and 2.0 times that of free xanthocyanin, respectively. This provides sufficient transdermal support for the skin care efficacy of xanthocyanin.

[0019] The above description is only an overview of the technical solution of this application. In order to better understand the technical means of this application and implement it in accordance with the contents of the specification, and to make the above and other objects, features and advantages of this application more obvious and understandable, the preferred embodiments of this application are described in detail below with reference to the accompanying drawings.

[0020] The above and other objects, advantages and features of this application will become more apparent to those skilled in the art from the following detailed description of specific embodiments in conjunction with the accompanying drawings. Attached Figure Description

[0021] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort. In all drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, the elements or parts are not necessarily drawn to scale.

[0022] Figure 1 This is the chemical structure diagram of xanthocyanin; Figure 2 A schematic diagram of the structure of human skin; Figure 3 A schematic diagram of the Franz diffusion cell in operation; Figure 4 A comparison diagram of the water solubility of xanthocyanin and its cyclodextrin inclusion complex; Figure 5 A 10×100x microscope image of xanthocyanin and its cyclodextrin inclusion complex; Figure 6 Comparison of room temperature stability of different formulations of xanthocyanin liposomes; Figure 7 Comparison of centrifugal stability of liposomes with different formulations of xanthocyanin; Figure 8 Microscopic images of liposomes with different formulations of xanthocyanin at 10×100x magnification; Figure 9The image shows the UV absorption curve of xanthocyanin in DMSO solution. Figure 10 High-performance liquid chromatograms of different concentrations of xanthocyanin; Figure 11 The standard curve of xanthocyanin; Figure 12 The cumulative transmittance curve of free xanthocyanin; Figure 13 The cumulative transmittance curve of the xanthocyanin cyclodextrin inclusion complex; Figure 14 This is a cumulative permeability curve of the xanthocyanin lipid carrier; Figure 15 This is a curve comparing the cumulative transmittance of the three samples. Detailed Implementation

[0023] To make the objectives, technical solutions, and advantages of the embodiments of this application clearer, the technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, not all embodiments. In the following description, specific details such as specific configurations and components are provided merely to help fully understand the embodiments of this application. Therefore, those skilled in the art should understand that various changes and modifications can be made to the embodiments described herein without departing from the scope and spirit of this application. In addition, for clarity and brevity, descriptions of known functions and structures are omitted in the embodiments.

[0024] It should be understood that the phrase "an embodiment" or "this embodiment" throughout the specification means that a specific feature, structure, or characteristic related to the embodiment is included in at least one embodiment of this application. Therefore, "an embodiment" or "this embodiment" appearing throughout the specification does not necessarily refer to the same embodiment. Furthermore, these specific features, structures, or characteristics can be combined in any suitable manner in one or more embodiments.

[0025] Furthermore, reference numerals and / or letters may be repeated in different examples within this application. Such repetition is for the purpose of simplification and clarity and does not in itself indicate a relationship between the various embodiments and / or settings discussed.

[0026] In this article, the term "and / or" is merely a description of the relationship between related objects, indicating that three relationships can exist. For example, A and / or B can mean: A exists alone, B exists alone, and A and B exist simultaneously. The term " / and" in this article describes another type of relationship between related objects, indicating that two relationships can exist. For example, A / and B can mean: A exists alone, and A and B exist alone. In addition, the character " / " in this article generally indicates that the related objects before and after it are in an "or" relationship.

[0027] In this article, the term "at least one" is merely a description of the relationship between related objects, indicating that there can be three relationships. For example, "at least one of A and B" can mean: A exists alone, A and B exist simultaneously, or B exists alone.

[0028] It should also be noted that, in this document, relational terms such as "first" and "second" are used only to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion.

[0029] Example 1: This example mainly introduces the preparation of xanthocyanin cyclodextrin inclusion complex.

[0030] The core active ingredient used in this embodiment is xanthocyanin (also known as WGX-50), whose chemical structure is N-(3,4-dimethoxyphenylethyl)-3-phenylacrylamide, belonging to the aromatic amide class of compounds, with the structure as follows: Figure 1 As shown. This embodiment prepares the xanthocyanin cyclodextrin inclusion complex under optimal process conditions, and the specific steps are as follows: 908 mg of methyl-β-cyclodextrin was accurately weighed and dissolved in 20 mL of deionized water; 249 mg of xanthocyanin was accurately weighed and dissolved in 5 mL of anhydrous ethanol. The cyclodextrin aqueous solution was heated to 60 °C with stirring until completely dissolved. Then, the xanthocyanin ethanol solution was slowly added, and the mixture was kept at 60 °C with stirring for 4 h. After the reaction was completed, the system was placed at 4 °C for 24 h, and then slowly filtered. The filter cake was washed twice with a small amount of anhydrous ethanol and dried in an electric thermostatic drying oven to constant weight to obtain a powdered xanthocyanin cyclodextrin inclusion complex.

[0031] The performance of the samples in this embodiment was characterized as follows: (1) Water solubility test: Prepare 0.2% xanthocyanin aqueous solution and 0.2% inclusion complex aqueous solution of this embodiment, respectively. After mixing evenly, sonicate for 10 min and observe the solubility. The results are as follows: Figure 4 As shown, the water solubility ranking is as follows: water solubility: inclusion complex 3 > inclusion complex 2 > inclusion complex 1 > xanthocyanin. In this embodiment, the inclusion complex > free xanthocyanin, and the solubility of the inclusion complex is significantly better.

[0032] (2) Microscopic observation: Excess amounts of xanthocyanin and the inclusion complex of this embodiment were weighed and dissolved in deionized water. A small amount of the powder-containing solution was then pipetted onto a glass slide, which was flattened with a coverslip and observed under a 10×100x optical microscope. The results are as follows: Figure 5As shown, the morphology of free xanthocyanin is lamellar, while the morphology of the inclusion compound in this embodiment is rod-shaped. The morphology of the two is significantly different, which can preliminarily prove the formation of the inclusion compound.

[0033] Comparative Example 1-1: The only difference from Example 1 is that the amount of deionized water used is 10 mL. The results show that cyclodextrin cannot be completely dissolved, cannot fully contact and react with xanthocyanin, the inclusion is insufficient, and the water solubility of the product is lower than that of Example 1.

[0034] Comparative Examples 1-2: The only difference from Example 1 was the incubation and stirring time, which was 3 hours. The results showed that insufficient inclusion time led to inadequate interaction between the host and guest components, resulting in poor inclusion effect and lower water solubility of the product compared to Example 1.

[0035] Example 2: This example mainly introduces the preparation of the xanthocyanin lipid carrier.

[0036] This embodiment prepares the zineb lipid carrier using the optimal formulation and process. The specific formulation and steps are as follows: The components are prepared according to the following mass fractions: Phase A consists of 3% lecithin, 0.3% cholesterol, 15% 1,2-propanediol, and 0.1% xanthocyanin; Phase B consists of 2% Tween 80 and deionized water to bring the total to 100%.

[0037] Accurately weigh each component of phase A into a beaker and stir at 60°C until fully dissolved and evenly dispersed. After phase B is heated to 60°C, phase B is slowly added to phase A, and the stirring speed is increased to 600 rpm for 10 min. Then, the mixture is placed in an ultrasonic cell disruptor and sonicated for 10 min. The mixture is then stirred at room temperature until cooled to obtain the xanthocyanin lipid carrier.

[0038] The stability of the samples in this embodiment was investigated: (1) Room temperature stability: The sample was placed in a room temperature environment and its appearance was observed after 24 hours. The results are as follows: Figure 6 As shown, liposome 1 > liposome 2 > liposome 3 > liposome 4. The sample in this embodiment has the least amount of precipitation and the best stability at room temperature.

[0039] (2) Centrifugation stability: A small amount of sample was placed in a centrifuge tube and centrifuged at 2000 rpm for 15 min. The separation of the samples was observed. The results are as follows: Figure 7 As shown, liposome 1 > liposome 2 > liposome 3 > liposome 4. In this embodiment, the sample has the least amount of stratified precipitation and the best centrifugal stability.

[0040] (3) Microscopic observation: Take a small amount of sample on a glass slide, flatten it with a coverslip, and observe it under a 10×100x optical microscope. The results are as follows: Figure 8 As shown, the samples in this embodiment are relatively uniformly dispersed, and the vesicle aggregation phenomenon is less than that in the other pairs.

[0041] Comparative Example 2-1: The only differences from Example 2 were the absence of ultrasonic treatment, the absence of Tween 80 in phase B, and a 1.0% xanthocyanin mass fraction. The results showed that the sample had the highest precipitation and the worst stability.

[0042] Comparative Example 2-2: The only difference from Example 2 is that phase B does not contain Tween 80 and the mass fraction of xanthocyanin is 1.0%. The results show that the stability is slightly better than that of Comparative Example 2-1, but there is still obvious stratification.

[0043] Comparative Examples 2-3: The only difference from Example 2 is that the mass fraction of xanthoside is 1.0%. The results show that the stability is better than that of Comparative Example 2-2, but the amount of precipitation is still higher than that of Example 2.

[0044] Example 3: This example mainly introduces the in vitro transdermal absorption test of different samples.

[0045] The skin is the core barrier for transdermal absorption, and its multi-layered structure is as follows: Figure 2 As shown, the skin consists of the epidermis, dermis, and subcutaneous tissue, with the stratum corneum being the main structure restricting the penetration of active ingredients. This embodiment uses the Franz vertical diffusion cell method to evaluate the transdermal performance of free xanthocyanin with two encapsulated compositions. The diffusion cell device structure is shown below. Figure 3 As shown, it consists of a supply chamber, a receiving chamber, a skin clamping structure, a temperature control system, and a magnetic stirring system. The specific experimental method is as follows: Solution preparation (1) Standard solution: Accurately weigh 5 mg of xanthoside and dissolve it in dimethyl sulfoxide (DMSO) to prepare a stock solution with a mass concentration of 500 μg / mL; dilute stepwise to obtain a series of xanthoside standard solutions with concentrations of 0, 2.5, 10, 25, 50, 100, 200, and 250 μg / mL.

[0046] (2) Supply pool solutions: Prepare 2% xanthocyanin DMSO solution, 2% DMSO solution of inclusion complex of Example 1, and lipid carrier of Example 2 (containing 0.1% xanthocyanin) as three sets of supply solutions.

[0047] (3) Receiving cell solution: DMSO was used as the transdermal receiving solution.

[0048] Establishment of quantitative analysis methods (1) Determination of maximum absorption wavelength: A 10 μg / mL solution of xanthocyanin in DMSO was prepared, and a full-band scan was performed using a UV spectrophotometer in the range of 190–350 nm. The results are as follows: Figure 9 As shown, the maximum absorption wavelength of xanthocyanin is 278 nm.

[0049] (2) Chromatographic conditions: An Agilent Plus C18 column (4.6 mm × 250 mm, 5 μm) was used, with an injection volume of 10 μL, a column temperature of 35 °C, and a detection wavelength of 278 nm; the mobile phase was a methanol-water solution with a volume ratio of 65:35.

[0050] (3) Standard curve preparation: After filtering the series of standard solutions through a 0.22 μm filter membrane, the solutions were injected and detected under the chromatographic conditions described above. The chromatograms at different concentrations are shown below. Figure 10 As shown; a standard curve was plotted with concentration on the x-axis and peak area on the y-axis, and the results are as follows. Figure 11 As shown, the xanthocyanin exhibits good linearity in the concentration range of 0–250 μg / mL, with the linear equation being y = 60.49003x + 78.92946 and a correlation coefficient of 0.99998, enabling accurate quantification.

[0051] In vitro transdermal experimental procedures Take fresh skin from the outer side of a pig's ear, remove excess fat, and select full-thickness skin without physical damage for cutting. Store the skin at -20℃ for no more than 30 days, and thaw at room temperature before use. Fix the skin between the supply and receiving chambers of a Franz vertical diffusion cell. The diffusion cell is placed in a 37℃ constant temperature water bath. The receiving chamber is magnetically stirred at 300 rpm to ensure the skin surface temperature is 32±1℃.

[0052] Different supply solutions (3g each) were applied to the skin surface. 200μL samples were collected from the receiving pool at 2, 4, 6, and 8 hours after application, with an equal volume of fresh receiving solution added simultaneously. The concentration of xanthocyanin in the receiving solution was determined using high-performance liquid chromatography (HPLC). The cumulative permeate and cumulative transmittance were calculated using the formulas. Three parallel experiments were conducted for each group.

[0053] The experimental results are as follows: (1) Free xanthocyanin: The cumulative permeability was 0.54%±0.29% at 2h, 1.16%±0.58% at 4h, 1.97%±0.96% at 6h, and 2.85%±1.13% at 8h. The transdermal efficiency was low. The cumulative permeability curve is shown in the figure. Figure 12 As shown.

[0054] (2) Piperin cyclodextrin inclusion complex: The cumulative permeation rate was 1.32%±0.76% at 2h, 3.27%±2.07% at 4h, 6.40%±3.31% at 6h, and 8.92%±4.33% at 8h, showing a significant permeation-enhancing effect. The cumulative permeation rate curve is shown in the figure. Figure 13 As shown.

[0055] (3) Piperidine lipid carrier: The cumulative permeation rate was 0.84%±0.51% at 2h, 1.82%±0.56% at 4h, 3.53%±1.20% at 6h, and 5.64%±1.29% at 8h. The permeation-enhancing effect was better than that of free piperidine. The cumulative permeation rate curve is shown in the figure. Figure 14 As shown.

[0056] The overall cumulative transmittance of the three groups of samples is as follows: Figure 15 As shown, the results indicate that both encapsulation systems can effectively improve the transdermal absorption efficiency of xanthocyanin, with the cyclodextrin inclusion complex exhibiting a better permeation-enhancing effect.

[0057] The above description is merely a preferred embodiment of the present invention and does not limit the scope of protection of the present invention. For those skilled in the art, the present invention can have various modifications and variations. Any changes, modifications, substitutions, integrations, and parameter alterations to these embodiments within the spirit and principles of the present invention, achieved through conventional substitutions or by achieving the same function without departing from the principles and spirit of the present invention, fall within the scope of protection of the present invention.

Claims

1. A method of preparing a xanthohumol encapsulated composition, characterized by, The encapsulation composition is a xanthocyanin cyclodextrin inclusion complex or a xanthocyanin lipid carrier. When the encapsulating composition is a xanthocyanin cyclodextrin inclusion complex, the preparation steps include: Step S101: Add methyl-β-cyclodextrin to deionized water, stir and heat until completely dissolved to obtain an aqueous phase; Step S102: Dissolve the xanthocyanin in anhydrous ethanol to obtain the alcohol phase; Step S103: Slowly add the alcohol phase dropwise into the aqueous phase, keep warm and stir to encapsulate; Step S104: After cooling, let stand for 24 hours, filter, wash the filter cake and dry it to constant weight; For every 908 parts by weight of methyl-β-cyclodextrin, there are 249 parts by weight of xanthoside and 20 parts by volume of deionized water. When the encapsulating composition is a xanthocyanin lipid carrier, the preparation steps include: Step S201: Prepare phase A: by mass fraction, lecithin 3%, cholesterol 0.3%, 1,2-propanediol 15%, and xanthocyanin 0.1%, mix and heat and stir until evenly dispersed; Step S202: Prepare phase B: By mass fraction, add Tween 80 2%, deionized water to make up to 100%, and heat. Step S203: Slowly add phase B to phase A, stir and then sonicate, stir and cool to room temperature.

2. A method of preparing a zanthin entrapped composition according to claim 1, wherein, In step S104 of the preparation of the xanthocyanin cyclodextrin inclusion complex, the filter cake is washed with anhydrous ethanol and dried by electric thermostatic forced-air drying.

3. The method of claim 1, wherein the preparation of the zanthoxylin-encapsulated composition is characterized by, In step S203 of the preparation of the xanthocyanin lipid carrier, the stirring speed is 600 rpm and the stirring time is 10 min; the ultrasonic treatment is performed using an ultrasonic cell disruptor for 10 min.

4. The method of claim 1, wherein the preparation of the zanthoxylin-encapsulated composition is characterized by, In step S203 of the preparation of the xanthocyanin lipid carrier, stirring and cooling are carried out at room temperature.

5. The method of claim 1, wherein the preparation of the zanthoxylin-encapsulated composition is characterized by, In the xanthocyanin lipid carrier, after Tween 80 dissociates, it is coated onto the surface of phospholipid vesicles through electrostatic interaction, increasing the repulsive force between vesicles.

6. A composition for the encapsulation of xanthones, characterized in that, It is prepared by the preparation method according to any one of claims 1 to 5.

7. A method of enhancing in vitro transdermal absorption of xanthones, characterized by, The xanthocyanin-encapsulated composition of claim 6 is applied to isolated skin for transdermal diffusion.

8. The method for improving the in vitro transdermal absorption of zanthopyll according to claim 7, characterized in that, Transdermal experiments were conducted using a Franz vertical diffusion cell, with full-thickness porcine ear skin as the transdermal barrier, dimethyl sulfoxide as the receiving solution, and the experimental temperature at 37°C. After 8 hours of transdermal treatment, the cumulative permeability of the xanthocyanin cyclodextrin inclusion complex was not less than 8.5%, and the cumulative permeability of the xanthocyanin lipid carrier was not less than 5.5%.

9. The application of the xanthocyanin-encapsulated composition according to claim 6 in the preparation of skin care cosmetics.

Images